PressMarch 23, 2023 Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
PressMarch 23, 2023 Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
PressMarch 23, 2023 Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
PressMarch 21, 2023 Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
PressMarch 21, 2023 Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
PressMarch 21, 2023 First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
BlogMarch 21, 2023 George McBride, CCO of Clerkenwell Health, Sits in the Investor Hotseat on March 30th
PressMarch 16, 2023 R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
PressMarch 15, 2023 Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
PressMarch 15, 2023 Filament Health Announces FDA Approval of Phase II Clinical Trial Studying Psilocybin for Methamphetamine Use Disorder
PressMarch 15, 2023 Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
PressMarch 10, 2023 Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
